Notable studies

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search

This page lists published ME/CFS studies that are notable, for particularly interesting findings, for controversial findings, or for their quality or their size.

General category Year of publication Study title Author(s) Notes Cohort size Blinded (double, single, not)
Epidemiological 2015 Institute of Medicine report Ellen Wright Clayton (Chair), Margarita Alegría, Lucinda Bateman, Lily Chu, Charles Cleeland, Ronald Davis, Betty Diamond, Theodore Ganiats, Betsy Keller, Nancy Klimas, A Martin Lerner, Cynthia Mulrow, Benjamin Natelson, Peter Rowe, Michael Shelanski
Epidemiological 2015 Pathways to prevention report Green CR, Cowan P, Elk R, O'Neil KM, Rasmussen AL
Epidemiological 2014 Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008–2012 Bakken IJ, Tveito K, Gunnes N, Ghaderi S, Stoltenberg C, Trogstad L, Håberg SE, Magnus P
Epidemiological 2013 The prevalence of chronic fatigue syndrome/myalgic encephalomyelitis: a meta-analysis Samantha Johnston, Ekua Brenu, Donald Staines, Sonya Marshall-Gradisnik
Epidemiological 2011 Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: a repeated cross-sectional study in primary care Luis Nacul, Eliana Lacerda, Derek Pheby, Peter Campion, Mariam Molokhia, Shagufta Fayyaz, Jose CDC Leite, Fiona Poland, Amanda Howe, Maria L Drachler
Epidemiological 2007 The burden of disease and injury in Australia 2003 Stephen Begg, Theo Vos, Barker B, Stevenson C, Stanley L, Lopez A
Epidemiological 2006 Prolonged Illness after infectious mononucleosis is associated with altered immunity but not with increased viral load Cameron, B., Bharadwaj, M., Burrows, J., Fazou, C., Wakefield, D., Hickie, I., Ffrench, R., Khanna, R. and Lloyd A. See also Model of Post Infective Fatigue Forming: the Dubbo Studies
Epidemiological 2006 Preliminary evidence of mitochondrial dysfunction associated with post-infective fatigue after acute infection with Epstein Barr virus Vernon, S., Whistler, T., Cameron, B., Hickie, I., Reeves, W. and Lloyd A. See also Model of Post Infective Fatigue Forming: the Dubbo Studies
Epidemiological 2006 Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study Ian Hickie, Tracey Davenport, Denis Wakefield, Vollmer-Conna U, Cameron B, Vernon SD, Reeves WC, Lloyd A
Epidemiological 2005 A systematic review describing the prognosis of chronic fatigue syndrome Ruth Cairns, Matthew Hotopf
Epidemiological 1996 Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups Anthony Komaroff, Fagioli LR, Doolittle TH, Gandek B, Gleit MA, Guerriero RT, Kornish RJ 2nd, Ware NC, Ware JE Jr, Bates DW
Immunological 2015 Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome Landi A, Broadhurst D, Suzanne Vernon, Tyrrell DL, Houghton M
Immunological 2015 Distinct plasma immune signatures in ME/CFS are present early in the course of illness Mady Hornig, Jose Montoya, Nancy Klimas, Levine S, Felsenstein D, Lucinda Bateman, Daniel Peterson, Gottschalk CG, Schultz AF, Che X, Eddy ML, Anthony Komaroff, Ian Lipkin
Immunological 2014 Deficient EBV-specific B-and T-cell response in patients with chronic fatigue syndrome Madlen Loebel, Kristin Strohschein, Carolin Giannini, Uwe Koelsch, Sandra Bauer, Cornelia Doebis, Sybill Thomas, Nadine Unterwalder, Volker von Baehr, Petra Reinke, Michael Knops, Leif G. Hanitsch, Christian Meisel, Hans-Dieter Volk, Carmen Scheibenbogen
Immunological 2012 Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis Ekua Brenu, Mieke L van Driel, Donald Staines, Kevin J Ashton, Sharni L Hardcastle, James Keane, Lotti Tajouri, Daniel Peterson, Sandra B Ramos, Sonya Marshall-Gradisnik
Immunological 2011 Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study Øystein Fluge , Ove Bruland, Kristin Risa, Anette Storstein, Einar K. Kristoffersen, Dipak Sapkota, Halvor Næss, Olav Dahl, Harald Nyland, Olav Mella
Immunological 2010 Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26 Fletcher MA, Zeng XR, Maher K
Immunological 2008 Neuroendocrine and immune network remodeling in chronic fatigue syndrome: an exploratory analysis Fuite J, Suzanne Vernon, Gordon Broderick
Immunological 2008 Cytokine Polymorphisms Have a Synergistic Effect on Severity of the Acute Sickness Response to Infection Vollmer-Conna U, Piraino B, Cameron B
Immunological 2007 Postinfective fatigue syndrome is not associated with altered cytokine production Vollmer-Conna U, Cameron B, Pavlovic D
Immunological 2006 A first study of cytokine genomic polymorphisms in CFS: positive association of TNF‐857 and IFNgamma 874 rare alleles Carlo‐Stella N, Badulli C, De S
Immunological 2005 Association of chronic fatigue syndrome with human leucocyte antigen class II alleles Smith J, Fritz EL, Jonathan Kerr
Metabolic 2016 Metabolic features of chronic fatigue syndrome Ronald Davis (Editor), Robert Naviaux, Jane C. Naviaux, Kefeng Li, A. Taylor Bright, William A. Alaynick, Lin Wang, Asha Baxter, Neil Nathan, Wayne Anderson, Eric Gordon Metabolomics showed that chronic fatigue syndrome is a highly concerted hypometabolic response to environmental stress that traces to mitochondria and was similar to the classically studied developmental state of dauer.
Metabolic 2014 Inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO2peak indicates functional impairment Betsy Keller, John Pryor, Ludovic Giloteaux
Metabolic 2012 Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls AT White, Alan Light, RW Hughen, TA Vanhaitsma, Kathleen Light
Metabolic 2009 Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects Alan Light, AT White, RW Hughen, Kathleen Light
Neurological 2016 Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study. Shan ZY, Richard Kwiatek, Burnet R, Del Fante P, Donald Staines, [[Sonya Marshall-Gradisnik]], Barnden LR.
Neurological 2015 Phase relationships are only measurable by the qEEG, giving us a unique window into the ME disease process Marcie Zinn, Mark Zinn, Leonard Jason See also [Phase Reset of the Default Mode Network.
Neurological 2015 There is poor agreement among researchers and clinicians about case definitions. Key domains are discussed. Leonard Jason, Marcie Zinn, Mark Zinn See also Lack of Agreement in Case Definitions hampers research.
Neurological 2015 Right arcuate fasciculus abnormality in chronic fatigue syndrome Michael Zeineh, Kang J, Atlas SW, Raman MM, Reiss AL, Jane Norris, Valencia I, Jose Montoya
Neurological 2007 Symptoms of autonomic dysfunction in chronic fatigue syndrome Julia Newton, O Okonkwo, K Sutcliffe, Seth A, Shin J, Jones DE
Treatment 2015 Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome Øystein Fluge, Olav Mella, Loebel M, Grabowski P, Heidecke H, Bauer S, Hanitsch LG, Wittke K, Meisel C, Reinke P, Volk HD, Carmen Scheibenbogen
Treatment 2015 B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment Øystein Fluge, Olav Mella, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, Kristoffersen EK, Sørland K, Bruland O, Dahl O
Treatment 2013 Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls Amolak Bansal, AS Bradley, B Ford
Treatment 2013 Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study Jarred Younger, Sean Mackey
Treatment 2012 The GI Microbiome and its Role in Chronic Fatigue Syndrome: A Summary of Bacteriotherapy Thomas J. Borody, Anna Nowak, Sarah Finalayson
Treatment 2011 Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study Øystein Fluge, Olav Mella, Bruland O, Risa K, Storstein A, Kristoffersen EK, Sapkota D, Næss H, Dahl O, Nyland H
Treatment 2010 Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels Jarred Younger, Noor N, McCue R, Mackey S
Treatment 2009 Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series Øystein Fluge, Olav Mella
Treatment 2008 Normalization of leaky gut in Chronic Fatigue Syndrome (CFS) is accompanied by a clinical improvement Michael Maes, Jean-Claude Leunis
Psychological 2011 The PACE trial Peter White, KA Goldsmith, AL Johnson, L Potts, R Walwyn, JC DeCesare, HL Baber, M Burgess, LV Clark, DL Cox, Jessica Bavinton, BJ Angus, Gabrielle Murphy, M Murphy, H O'Dowd, D Wilks, P McCrone, Trudie Chalder, Michael Sharpe
Psychological 2005 The Placebo Response in the Treatment of Chronic Fatigue Syndrome: A Systematic Review and Meta-Analysis Hyong Jin Cho, Matthew Hotopf, Simon Wessely Found that the placebo response was actually lower in CFS patients
Psychological 2014 Exercise therapy for chronic fatigue syndrome Cochrane: Lillebeth Larun, Kjetil G. Brurberg, Jan Odgaard-Jensen, Jonathan R Price


The information provided at this site is not intended to diagnose or treat any illness.

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history